PAHCHealthcare · Drug Manufacturers - Specialty & GenericThe 4 Wall Street analysts covering Phibro Animal Health Corp. hold a median 12-month price target of $43 — +12.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 92 of 100 as at 10 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Phibro Animal Health Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PAHC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +12.3% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 May 2026 | Citigroup | Maintains | Neutral | $62 → $44 |
| 14 May 2026 | Citigroup | Maintains | Neutral | — |
| 15 Apr 2026 | Citigroup | Initiates | Neutral | — |
| 7 Nov 2025 | JP Morgan | Maintains | Overweight | — |
| 29 Aug 2025 | B of A Securities | Maintains | Underperform | — |
| 7 July 2025 | JP Morgan | Upgrade | Overweight | — |
| 25 June 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 8 May 2025 | Morgan Stanley | Maintains | Equal-Weight | — |
| 10 Feb 2025 | Barclays | Maintains | Underweight | — |
| 17 Dec 2024 | Morgan Stanley | Maintains | Equal-Weight | — |
| 12 Nov 2024 | Barclays | Maintains | Underweight | — |
| 10 Sept 2024 | JP Morgan | Initiates | Neutral | — |
| 30 Aug 2024 | B of A Securities | Maintains | Underperform | — |
| 10 May 2024 | Barclays | Maintains | Underweight | — |
| 9 Nov 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 1 Sept 2023 | Roth MKM | Reiterates | Buy | — |
| 31 Aug 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
| 29 Aug 2023 | Roth MKM | Reiterates | Buy | — |
| 27 July 2023 | Morgan Stanley | Reiterates | Equal-Weight | — |
| 4 May 2023 | Morgan Stanley | Maintains | Equal-Weight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PAHC appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 9 Oct 2026, Phibro Animal Health Corp. returned +4.2% against +17.3% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 44% of US stocks
Cheaper than 68% of US stocks
Cheaper than 24% of US stocks
Cheaper than 40% of US stocks
Higher than 38% of US stocks
Higher than 63% of US stocks
Higher than 40% of US stocks
Higher than 65% of US stocks
Higher than 64% of US stocks
Higher than 87% of US stocks
Higher than 89% of US stocks
Higher than 73% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Phibro Animal Health Corp. has a market value of $1.6B and an enterprise value of $2.3B.
Revenue in the twelve months to 30 June 2026: $1.5B. The latest quarter grew 4.8% year on year.
Net income over the same four quarters: $99.7M, a 6.6% net margin.
Diluted earnings per share, trailing twelve months: $2.44.
Free cash flow in the twelve months to 30 June 2026: $9.9M, after $59.1M of capital spending.
Phibro Animal Health Corp. spent $19.5M on dividends in the twelve months to 30 June 2026.
Trailing P/E: 15.8×; forward P/E: 10.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 1.25%, paying out 20% of earnings.
Phibro Animal Health Corp. employs 2,605 people — $583K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Phibro Animal Health Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
The article notes that Phibro Animal Health’s Animal Health segment is benefiting from growth in MFA, vaccines and mineral nutrition. It also identifies tariffs, costs and currency swings as risks to the company’s outlook.
Why it matters — PAHC watchers may weigh the cited growth drivers against the operational and currency risks highlighted in the article.
A Zacks Investment Research article compares Phibro Animal Health (PAHC) with Haemonetics (HAE) as potential value options within the Medical - Products sector, raising the question of which presents the better value opportunity. The piece evaluates both stocks from a value-investing perspective.
Why it matters — A PAHC watcher would care because the comparison offers a value-focused evaluation of the company relative to a sector peer, providing context on how analysts perceive its investment appeal.
Phibro Animal Health Corp. (PAHC) reported earnings 30 days ago, and its stock has since declined 6.7%. The report examines what may be next for the company following the earnings release.
Why it matters — PAHC watchers would care because the stock has fallen notably since the earnings report, prompting questions about the company's near-term outlook.
Zacks Investment Research included Phibro Animal Health Corp. (PAHC) on its Zacks Rank #1 (Strong Buy) momentum stocks list dated September 21st, 2026, alongside SEI and SDRL.
Why it matters — A PAHC watcher would care because the company was highlighted on a notable momentum stock ranking, signalling recognition of its recent performance.
Zacks Investment Research published a comparison of Phibro Animal Health (PAHC) and Haemonetics (HAE) as potential value opportunities for investors in the Medical - Products sector. The article poses the question of which of the two stocks offers the better value right now.
Why it matters — The piece highlights PAHC as a stock in the medical-products sector being evaluated against a peer for value-investing appeal, which could draw attention to the company.
The 4 Wall Street analysts covering Phibro Animal Health Corp. have a median 12-month price target of $43, with estimates ranging from $35 to $55. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering Phibro Animal Health Corp., 1 rate it a Buy, 2 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Phibro Animal Health Corp. 92 out of 100 across roughly 4,600 US stocks as at 10 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 10 Oct 2026, Phibro Animal Health Corp. ranks 92 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +12.3% from the last close, and Ticker Nerd's factor model ranks Phibro Animal Health Corp. 92 out of 100 as at 10 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Phibro Animal Health Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PAHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $55 over the next 12 months.
Phibro Animal Health Corp. returned +4.2% over the 12 months to 9 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Phibro Animal Health Corporation Class A Common Stock represents ownership in Phibro Animal Health Corporation, a global animal health and mineral nutrition company. Phibro develops, manufactures, and markets products for food-producing and companion animals, supporting sectors such as poultry, swine, beef and dairy cattle, aquaculture, and pets.
The most recent item we track (Zacks Investment Research, 8 Oct 2026): "Is it the Right Time to Add Phibro Stock to Your Portfolio?". The article notes that Phibro Animal Health’s Animal Health segment is benefiting from growth in MFA, vaccines and mineral nutrition. It also identifies tariffs, costs and currency swings as risks to the company’s outlook.
Phibro Animal Health Corporation Class A Common Stock represents ownership in Phibro Animal Health Corporation, a global animal health and mineral nutrition company. Phibro develops, manufactures, and markets products for food-producing and companion animals, supporting sectors such as poultry, swine, beef and dairy cattle, aquaculture, and pets. Its portfolio spans animal health solutions, mineral nutrition products, and performance products used in livestock production and animal care. The company serves customers across the agricultural and veterinary supply chains, where its offerings help address nutrition, health, and productivity needs in animal operations. Phibro Animal Health Corporation is headquartered in Teaneck, New Jersey, and its Class A common stock is one of the company’s primary publicly traded equity classes.
CEO Mr. Daniel M. Bendheim J.D. · 2,605 employees · United States · https://www.pahc.com
